Calibre What Science Can Do

This website contains promotional content about AstraZeneca Medications. This website is intended for healthcare professionals involved in the Acute Coronary Syndrome care pathway, such as hospital specialists from cardiology and cardiology-related departments, including A&E and elderly care, as well as GPs with a specific interest in cardiology, nurses, pharmacists and payers with budget responsibilities in cardiology.

Hot topics

June 2018 - New!

The value of risk scores for assessing the role of long-term dual antiplatelet therapy (DAPT) in non-ST-elevation myocardial infarction (NSTEMI) patients
Prof. Anthony Gershlick

Prof. Anthony Gershlick

Consultant cardiologist since 1989. Made Professor of Interventional Cardiology at University of Leicester 2008. Major interest has been in acute cardiology and intervention for coronary artery disease. Was the first in the UK to undertake clinical brachytherapy,  the first to implant a drug eluting stent and the first to treat a patient in the UK with stem cells from the leg muscle and the first to implant a Bio-absorbable stent.

Lead faculty for multiple major International meetings. Research interests over the years have covered the basic science/pre-clinical area as well as the application of proven basic concepts as applied to and assessed in the clinical arena. “As long ago as the early 1990s my lab investigated ways of delivering drugs loaded onto the stents themselves in order to reduce the unwanted tissue  response. In 1996 we published a benchmark pre-clinical study in Circulation that demonstrated the efficacy of drugs delivered locally in this way. Current pre-clinical projects include assessing whether loading of stents with HIF- (a growth factor switch molecule) for treating difficult CTOs. He devised, ran and analysed the REACT trial and was co-PI of the NEJM published STREAM Trial.

Continuous care and treatment management for non-ST-elevated myocardial infarction (NSTEMI) patients
Dr. Nick Pegge & Dr. Emmanuel Ako

Dr. Nick Pegge

Qualified from Jesus College, Cambridge and St Thomas', London.

Postgraduate training at Royal Sussex County Hospital, Brighton; Royal Free Hospital and St George's Hospital, London; Singleton and Morriston Hospitals, Swansea; University Hospital of Wales, Cardiff.

Fellowship in Interventional Cardiology, University Hospital, Frankfurt am Main, Germany (2003).

Professional interests: All forms of cardiology, especially coronary intervention, heart failure, arrhythmias, pacing and complex device therapy.

Expert witness for GMC.

Chair of Trust Joint Private Practice CommitteeProfessional memberships: British Cardiovascular Society British Cardiovascular Intervention Society European Society of Cardiology

Dr. Emmanuel Ako

Dr Emmanuel Ako is a Consultant Cardiologist with a specialist interest in Coronary Intervention and the treatment of coronary artery disease. He also has expertise in cardiovascular complications in Haemoglobinopathies such as Thalassaemia and Sickle Cell disease. He works at both Chelsea and Westminster NHS Foundation Trustand the Royal Brompton Hospital NHS Trust.

He studied medicine at University College London where he graduated with distinction in 2005 and awarded several prizes including an award from the Vandervell foundation, PPP foundation and NIHR.

He completed an intercalated BSc in Physiology supported by the prestigious award from the Physiological society achieving a 1st class Honours. He completed his postgraduate medical training at St Georges, the London Chest and the Heart Hospital in London. He achieved his MRCP before dual accrediting in general internal medicine and cardiology in North East Thames. He trained in interventional Cardiology at the Heart Hospital and Barts Heart Centre. Dr Ako gained complimentary training in cardiac MRI and Cardiac CT at Great Ormond Street and Barts Heart Centre.

In addition to his clinical commitments, Dr Ako has been involved in stem cell research for ischaemic heart disease and the effects of thalassemia and sickle cell disease onthe cardiovascular system. He has an interest in cardiac MRI focusing on its use in pulmonary hypertension in haemoglobinopathies. He is a winner of the American College of Cardiology young investigator award in Chicago for research into haemoglobinopathy and a finalist at the SCMR Early Career Awards in Los Angelesand the RSM Presidents Medal in London.

Dr Ako is active in clinical education and research. He also has expertise in simulation based training in cardiology. He has been involved in developing a very successful simulation based training programme with Imperial College London which has been rolled out across the UK aimed at cardiologists and anaesthetists.

Dr Ako has published various articles, presented at national and international conferences and is a frequent speaker in public engagement workshops internationally.

January 2018

Real world implementation of dual anti-platelet therapy (DAPT) in high-risk, post-myocardial infarction (MI) patients: Where are we now?
Professor Robert Storey

Professor Robert Storey

Professor Robert Storey is a professor of cardiology at the University of Sheffield. He is also Academic Director and an honorary consultant cardiologist for the Cardiology and Cardiothoracic Surgery Directorate at Sheffield Teaching Hospitals NHS Foundation Trust. He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention.

Professor Storey served as a member of the executive committees for the DISPERSE2, PLATO and PEGASUS-TIMI 54 studies, leading the platelet function sub-studies for these trials and of the steering committees for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committees for the COMPLETE, RAPID CTCA, SENIOR RITA and AUGUSTUS studies. He has been the head of a thrombosis research group at the University of Sheffield since 2002. 

Professor Storey was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012–2014 and has been a task force member for several ESC guidelines on non-ST-elevation acute coronary syndromes (2011 and 2015) and dyslipidaemias (2011).

Long-term dual anti-platelet therapy (DAPT) in high-risk, post myocardial infarction (MI) patients: Where are we now?
Professor Philippe Gabriel Steg

Professor Philippe Gabriel Steg

Dr Philippe Gabriel Steg is a professor of cardiology at Université Paris Diderot and the National Heart and Lung Institute of Imperial College London. He is also an interventional cardiologist and Chief of the Cardiology Department at Hôpital Bichat, Assistance Publique-Hôpitaux de Paris.

Dr Steg participates in the leadership of many trials in coronary artery disease and is currently Chair/co-Chair or principal investigator of several large clinical trials or registries such as ODYSSEY Outcomes, CLARIFY, THEMIS, REALITY, and SCORED. He is Chair of the FACT: French Alliance for Cardiovascular Clinical Trials academic research network, was co-Chair of the REACH registry and the GRACE registry publication committee, and participated in numerous data monitoring committees or clinical events committees.

Dr Steg is co-Coordinator of the Département Hospitalo-Universitaire FIRE affiliated with INSERM, Université Paris Diderot and Assistance Publique – Hôpitaux de Paris, and Coordinator of the iVASC research consortium. He has authored over 1,000 articles in international peer-reviewed journals, is Associate Editor for Circulation and on the editorial board for the European Heart Journal. He received the silver medal of the European Society of Cardiology (ESC) in 2011 and co-chaired the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.

May 2017

The atherothrombotic story
Professor Azfar Zaman

Azfar Zaman is a professor of clinical cardiology at Freeman Hospital and Newcastle University, Newcastle upon Tyne and Head of Coronary Intervention and Director of the cardiac catheter laboratories at Freeman Hospital. He completed his postgraduate training in cardiology at regional centres in Leeds, London and Cardiff, following which, he was awarded a Fulbright Scholarship and a 2-year British Heart Foundation International Fellowship to study vascular biology at Mount Sinai Medical Center, New York.

As Clinical Director for Cardiovascular Research, and with interests in clinical research, atherothrombosis in diabetes and clinical trials, Professor Zaman has been awarded research grants from the British Heart Foundation, Diabetes Wellness Research Foundation and the National Institute for Health Research. He currently leads a team of 16 individuals conducting clinical trials and research in cardiology and has built an impressive publication record with Professor Azfar Zaman over 100 peer-reviewed publications.

Platelet testing following coronary stenting—is the debate over?
Professor Gilles Montalescot

Gilles Montalescot is a professor of cardiology at the Pitié-Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing interventional cardiologist and has extensive experience in basic and clinical research. Professor Montalescot is Director of the INSERM research unit UMRS_1166 on thrombosis and Chairman of the ACTION study group, an academic research organisation based at Pitié-Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery Disease guidelines of the European Society of Cardiology.

Professor Montalescot has received several awards in his country including the J. Valade prize from the Fondation de France and the J. Escalle award from the National Academy of Medicine. Professor Montalescot is a member of several editorial boards and has published over 400 peer-reviewed original articles in journals such as NEJM, JAMA, The Lancet and Circulation. Internationally, Professor Montalescot has also been an invited plenary session speaker at all the major congresses such as the European Society of Cardiology, the American College of Cardiology and the American Heart Association.